Serum thyroglobuline at the time of remnant ablation in predicting clinical outcome in patients with low risk differentiated thyroid carcinoma

Basit Öğe Kaydı
dc.contributor.authorAkgun, A.
dc.contributor.authorErdim, O.
dc.contributor.authorYazici, B.
dc.contributor.authorOzcan, Z.
dc.contributor.authorOzkilic, H.
dc.date.accessioned2019-10-27T19:17:26Z
dc.date.available2019-10-27T19:17:26Z
dc.date.issued2006
dc.departmentEge Üniversitesien_US
dc.identifier.endpageS328en_US
dc.identifier.issn1619-7070
dc.identifier.startpageS328en_US
dc.identifier.urihttps://hdl.handle.net/11454/38381
dc.identifier.volume33en_US
dc.identifier.wosWOS:000202967401188en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofEuropean Journal of Nuclear Medicine and Molecular Imagingen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleSerum thyroglobuline at the time of remnant ablation in predicting clinical outcome in patients with low risk differentiated thyroid carcinomaen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu